FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166984768> ?p ?o ?g. }

• W3166984768 endingPage "e21164" @default.
• W3166984768 startingPage "e21164" @default.
• W3166984768 abstract "e21164 Background: The treatment of advanced non-small cell lung cancer (aNSCLC) has tremendously changed during the last few years, especially, since immune checkpoint inhibitors (ICIs) were incorporated in the daily clinical practice. However, clinical useful biomarkers remain an unmet need. Recently, our group established and proposed a new score, Patras Immunotherapy Score (PIOS), which was found to have predictive and prognostic value in a discovery group with aNSCLC patients treated with nivolumab or pembrolizumab. The objective of the current study was to validate our initial observation and confirm the clinical significance of PIOS formula in an external and multicentric cohort of aNSCLC patients. Methods: PIOS is a baseline formula derived by combining the following non-interventional clinical parameters, Performance Status (PS), Body Mass Index (BMI), age and Line Of Treatment (LOT) and it is calculated as PIOS = (PS×BMI)/(LOT×AGE). In the current multicenter study, 626 aNSCLC patients, treated with nivolumab or pembrolizumab monotherapy, were retrospectively selected, blindly to the clinical outcome, and enrolled. The primary endpoints of this study were to investigate the predictive and prognostic value of PIOS in terms of progression free survival (PFS), overall survival (OS) and best overall response. Results: Firstly, PIOS was associated with best overall response. Following a two-tier model, patients who had progressed (PD) had lower scores than those with stable disease (SD), partial response (PR) or complete response (CR) (p < 0.001). This association remained significant using a four-tier model (PD, SD, PR and CR) for evaluation of best overall response (p < 0.001). In addition, predictive significance of PIOS score also persisted using a binary logistic regression analysis, adjusted for disease stage and PD-L1 status (p = 0.002, OR 0.578, 95% CI 0.408-0.821). Furthermore, patients with higher PIOS score had longer PFS compared to patients with lower PIOS score (ΗΡ 0.621, 95% CI 0.470-0.821, p = 0.001), while multivariate analysis for PFS, adjusted for clinical stage and PD-L1, confirmed the predictive value of PIOS score (HR 0.651, 95% CI 0.492-0.863, p = 0.003). Moreover, PIOS score was also associated with prognosis (p < 0.001). The median OS for the favorable group was 778 days compared to 341 days for the unfavorable group with low PIOS score (HR = 0.608, 95% CI 0.482-0.766, p < 0.001) at univariate analysis. This association remained statistically significant (HR 0.620, 95% CI 0.492-0.783, p < 0.001) after adjusting for PD-L1 expression. Conclusions: These data provide further validation for PIOS as predictive and prognostic biomarker in aNSCLC patients treated with nivolumab or pembrolizumab monotherapy." @default.
• W3166984768 created "2021-06-22" @default.
• W3166984768 creator A5002201877 @default.
• W3166984768 creator A5004779245 @default.
• W3166984768 creator A5005489735 @default.
• W3166984768 creator A5005730021 @default.
• W3166984768 creator A5009951629 @default.
• W3166984768 creator A5010139507 @default.
• W3166984768 creator A5013680239 @default.
• W3166984768 creator A5013973547 @default.
• W3166984768 creator A5015401016 @default.
• W3166984768 creator A5022772346 @default.
• W3166984768 creator A5029419201 @default.
• W3166984768 creator A5043943818 @default.
• W3166984768 creator A5044610238 @default.
• W3166984768 creator A5046892627 @default.
• W3166984768 creator A5049479861 @default.
• W3166984768 creator A5049509860 @default.
• W3166984768 creator A5064636994 @default.
• W3166984768 creator A5066218201 @default.
• W3166984768 creator A5078996737 @default.
• W3166984768 creator A5087255417 @default.
• W3166984768 date "2021-05-20" @default.
• W3166984768 modified "2023-09-26" @default.
• W3166984768 title "Predictive and prognostic significance of PIOS (Patras Immunotherapy Score) model in patients with advanced NSCLC treated with nivolumab or pembrolizumab: Results from a validation cohort." @default.
• W3166984768 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e21164" @default.
• W3166984768 hasPublicationYear "2021" @default.
• W3166984768 type Work @default.
• W3166984768 sameAs 3166984768 @default.
• W3166984768 citedByCount "0" @default.
• W3166984768 crossrefType "journal-article" @default.
• W3166984768 hasAuthorship W3166984768A5002201877 @default.
• W3166984768 hasAuthorship W3166984768A5004779245 @default.
• W3166984768 hasAuthorship W3166984768A5005489735 @default.
• W3166984768 hasAuthorship W3166984768A5005730021 @default.
• W3166984768 hasAuthorship W3166984768A5009951629 @default.
• W3166984768 hasAuthorship W3166984768A5010139507 @default.
• W3166984768 hasAuthorship W3166984768A5013680239 @default.
• W3166984768 hasAuthorship W3166984768A5013973547 @default.
• W3166984768 hasAuthorship W3166984768A5015401016 @default.
• W3166984768 hasAuthorship W3166984768A5022772346 @default.
• W3166984768 hasAuthorship W3166984768A5029419201 @default.
• W3166984768 hasAuthorship W3166984768A5043943818 @default.
• W3166984768 hasAuthorship W3166984768A5044610238 @default.
• W3166984768 hasAuthorship W3166984768A5046892627 @default.
• W3166984768 hasAuthorship W3166984768A5049479861 @default.
• W3166984768 hasAuthorship W3166984768A5049509860 @default.
• W3166984768 hasAuthorship W3166984768A5064636994 @default.
• W3166984768 hasAuthorship W3166984768A5066218201 @default.
• W3166984768 hasAuthorship W3166984768A5078996737 @default.
• W3166984768 hasAuthorship W3166984768A5087255417 @default.
• W3166984768 hasConcept C121608353 @default.
• W3166984768 hasConcept C126322002 @default.
• W3166984768 hasConcept C143998085 @default.
• W3166984768 hasConcept C2776256026 @default.
• W3166984768 hasConcept C2777701055 @default.
• W3166984768 hasConcept C2780030458 @default.
• W3166984768 hasConcept C2780057760 @default.
• W3166984768 hasConcept C71924100 @default.
• W3166984768 hasConcept C72563966 @default.
• W3166984768 hasConceptScore W3166984768C121608353 @default.
• W3166984768 hasConceptScore W3166984768C126322002 @default.
• W3166984768 hasConceptScore W3166984768C143998085 @default.
• W3166984768 hasConceptScore W3166984768C2776256026 @default.
• W3166984768 hasConceptScore W3166984768C2777701055 @default.
• W3166984768 hasConceptScore W3166984768C2780030458 @default.
• W3166984768 hasConceptScore W3166984768C2780057760 @default.
• W3166984768 hasConceptScore W3166984768C71924100 @default.
• W3166984768 hasConceptScore W3166984768C72563966 @default.
• W3166984768 hasIssue "15_suppl" @default.
• W3166984768 hasLocation W31669847681 @default.
• W3166984768 hasOpenAccess W3166984768 @default.
• W3166984768 hasPrimaryLocation W31669847681 @default.
• W3166984768 hasRelatedWork W2091729697 @default.
• W3166984768 hasRelatedWork W2342781363 @default.
• W3166984768 hasRelatedWork W2767114511 @default.
• W3166984768 hasRelatedWork W2786497694 @default.
• W3166984768 hasRelatedWork W2898071776 @default.
• W3166984768 hasRelatedWork W2981883049 @default.
• W3166984768 hasRelatedWork W2988525911 @default.
• W3166984768 hasRelatedWork W3021504039 @default.
• W3166984768 hasRelatedWork W3215044659 @default.
• W3166984768 hasRelatedWork W4322754005 @default.
• W3166984768 hasVolume "39" @default.
• W3166984768 isParatext "false" @default.
• W3166984768 isRetracted "false" @default.
• W3166984768 magId "3166984768" @default.
• W3166984768 workType "article" @default.